
Biovyt Pharma Private Limited
Company manufactures and trades pharmaceuticals, healthcare products, and medical goods.
Company manufactures and trades pharmaceuticals, healthcare products, and medical goods.
Indore, Madhya Pradesh, India
+91-XXXXXXXXXX
U24290MP2021PTC057549
057549
Private Limited Indian Non-Government Company
21 Sep 2021
-
-
Unlisted
Roc Gwalior
Name | Designation | Appointment Date | Status |
---|---|---|---|
Vivek Raghuvanshi ![]() | Director | 21-Sep-2021 | Current |
Himanshu Choudhary ![]() | Director | 21-Sep-2021 | Current |
Dhiraj Raghuvanshi ![]() | Director | 21-Sep-2021 | Current |
Enhance accessibility to Biovyt Pharma's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue | |||||||
Revenue from Operations | |||||||
Total Assets | |||||||
Profit or Loss | |||||||
Net Worth | |||||||
EBITDA |
Unlock access to Biovyt Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Vivek Raghuvanshi is a mutual person
Vivek Raghuvanshi is a mutual person
Himanshu Choudhary is a mutual person
There are no open charges registered against the company as per our records.
Biovyt Pharma has a workforce of 0 employees as of Mar 29, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Biovyt Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Biovyt Pharma's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Vivek Raghuvanshi was appointed as a Director was appointed as a Director on 21 Sep 2021 & has been associated with this company since 3 years 5 months .
Himanshu Choudhary was appointed as a Director was appointed as a Director on 21 Sep 2021 & has been associated with this company since 3 years 5 months .
Dhiraj Raghuvanshi was appointed as a Director was appointed as a Director on 21 Sep 2021 & has been associated with this company since 3 years 5 months .
Biovyt Pharma Private Limited was registered on 21 Sep 2021 with Roc Gwalior & aged 3 years 5 months as per MCA records.
Biovyt Pharma Private Limited was incorporated on 21 Sep 2021.
The authorized share capital of Biovyt Pharma Private Limited is ₹ 1.50 M and paid-up capital is ₹ 0.15 M.
Currently 3 directors are associated with Biovyt Pharma Private Limited.
As per Ministry of Corporate Affairs (Mca), the registered address of Biovyt Pharma Private Limited is Flat No. 202 4-E Aakar Regency Scheme No.71, Gumasta Nagar India, Indore, Madhya Pradesh, 452009.
The corporate identification number (CIN) of Biovyt Pharma Private Limited is U24290MP2021PTC057549 and the company number is 057549 as per Ministry of Corporate Affairs (MCA).
Search company & director profiles for free and gain access to critical business data.